In early 2022, Paul Chaplin, President and CEO of Copenhagen-based Bavarian Nordic A/S, was readying for a “rather heavy loss for the company.”
“It was going to be a challenging year, both because it was a huge year of investment in two Phase...
Mpox And Newfound ‘Punching Power’ Are Bringing Bavarian Nordic Closer To $1bn Target
Bavarian Nordic managed to change its financial story in 2022 when its smallpox vaccine, Jynneos, became a critical tool in the global response to the mpox pandemic. CEO Paul Chaplin speaks to In Vivo about what this year holds in store.
